Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177 LNC1008
- Development stage
- Phase 1
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Lutetium Lu 177 LNC1008 (177Lu-LNC1008) is a target-specific therapeutic radiopharmaceutical (radioligand therapy) developed by Yantai Lannacheng Biotechnology, a subsidiary of Dongcheng Pharmaceutical. It consists of a targeting ligand (LNC1008) that specifically binds to integrin αvβ3 (alpha-v beta-3), conjugated to the beta-emitting radionuclide lutetium-177 (177Lu). Integrin αvβ3 is highly expressed in various solid tumors and tumor-associated neovasculature, but has low expression in normal tissues. By delivering targeted radiation directly to integrin αvβ3-positive tumor cells, 177Lu-LNC1008 induces DNA damage and cell death while minimizing damage to healthy tissues. It is currently in Phase 1 clinical development for the treatment of integrin αvβ3-positive advanced malignant solid tumors.
- Other names
- 镥[177Lu]-LNC1008镥[177Lu]-LNC1008注射液
02
Targets
DNAαVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on lutetium Lu 177 LNC1008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177 LNC1008.